SPRY

ARSB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

20%

Probability

Target price

$32.00

+259.6% vs current

Most likely

Base case

50%

Probability

Target price

$18.00

+102.2% vs current

B-

Bear case

30%

Probability

Target price

$4.50

-49.4% vs current

AI sentiment snapshot

Latest data as of 2026-05-18

AI commentary

Post-print tone is mixed: the company delivered revenue growth and a string of access milestones, but the EPS miss and heavy spend led to a 6.5% close-day decline before a 5.0% after-hours bounce. No analyst revision data were available in the packet, so this remains a monitoring view rather than a confirmed rerate.

RankAlpha Sentiment Codex - 2026-05-18

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-15eventFlorida Medicaid added unrestricted coverageMedium impact

Florida added neffy to its unrestricted Medicaid formulary, taking the total to nine state Medicaid plans and supporting broader access momentum [#8-K-2026-05-15].

2026-05-18catalystQ1 earnings print was mixed and shares sold offMedium impact

ARS reported Q1 2026 revenue of $22.7M, including $17.5M of U.S. neffy product revenue, but the market focused on the EPS miss and heavy SG&A; SPRY closed at $7.43 (-6.5% on 5/15) before rebounding to $7.80 after hours [#8-K-2026-05-15].

2026-08-16eventCVS Caremark formulary decision is the next access catalystMedium impact

Management said the CVS Caremark proposal is in the final stages of approval, with a target July 1 effective date and an early-June update expected; a favorable result would improve payer access and gross-to-net economics [#8-K-2026-05-15].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-18 • Updated nightlySource: Internal modelMethodology